基本數據
| CIK | 1733294 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Generation Bio Co.
SEC Filings (Chronological Order)
本頁面提供了一個完整的、按時間順序排列的美國證券交易委員會（SEC）申報文件列表，不包括我們在其他地方提供的所有權申報。
| February 19, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-39319 Generation Bio Co. (Exact name of registrant as specified in its |
|
| February 9, 2026 |
EX-99.(a)(5)(B) Exhibit (a)(5)(B) XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc. - Generation Bio Stockholders Received $4.2913 Per Share in Cash Plus a Contingent Value Right - EMERYVILLE, Calif., February 9, 2026 (GLOBE NEWSWIRE) – XOMA Royalty Corporation (NASDAQ: XOMA) (“XOMA Royalty” or the “Company”), a biotechnology royalty aggregator playin |
|
| February 9, 2026 |
As filed with the Securities and Exchange Commission on February 9, 2026 As filed with the Securities and Exchange Commission on February 9, 2026 Registration No. |
|
| February 9, 2026 |
As filed with the Securities and Exchange Commission on February 9, 2026 As filed with the Securities and Exchange Commission on February 9, 2026 Registration No. |
|
| February 9, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2026 Generation Bio Co. (Exact name of registrant as specified in its charter) Delaware 001-39319 81-4301284 (State or other jurisdiction of incorporation) (Commission Fil |
|
| February 9, 2026 |
As filed with the Securities and Exchange Commission on February 9, 2026 As filed with the Securities and Exchange Commission on February 9, 2026 Registration No. |
|
| February 9, 2026 |
SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Generation bio co. * * * * * * * * Exhibit 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF Generation bio co. * * * * * * * * I. The name of this corporation is Generation Bio Co. (the “Corporation”). II. The registered office of the Corporation in the State of Delaware is Corporation Trust Center, 1209 Orange Street in the City of Wilmington, County of New Castle 19801, and the name of the registered agent of the C |
|
| February 9, 2026 |
As filed with the Securities and Exchange Commission on February 9, 2026 As filed with the Securities and Exchange Commission on February 9, 2026 Registration No. |
|
| February 9, 2026 |
As filed with the Securities and Exchange Commission on February 9, 2026 As filed with the Securities and Exchange Commission on February 9, 2026 Registration No. |
|
| February 9, 2026 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) GENERATION BIO CO. (Name of Subject Company (Issuer)) XRA 7 CORP. (Name of Filing Persons (Co-Offeror)) XOMA ROYALTY CORPORATION (Name of Filing Persons (Co-Offeror)) Common Stock, Par Value |
|
| February 9, 2026 |
CONTINGENT VALUE RIGHTS AGREEMENT Exhibit 2.2 CONTINGENT VALUE RIGHTS AGREEMENT This CONTINGENT VALUE RIGHTS AGREEMENT, dated as of February 9, 2026 (this “Agreement”), is entered into by and among XOMA Royalty Corporation, a Nevada corporation (“Parent”), XRA 7 Corp., a Delaware corporation and a wholly owned Subsidiary of Parent (“Merger Sub” and together with Parent, the “Buyer Entities”) and Broadridge Corporate Issuer Solutio |
|
| February 9, 2026 |
Exhibit 10.1 LEASE TERMINATION AGREEMENT THIS LEASE TERMINATION AGREEMENT (this “Agreement”) is entered into as of this 9th day of February, 2026 (“Execution Date”), by and between BMR-ROGERS STREET LLC, a Delaware limited liability company (“Landlord”), and GENERATION BIO CO., a Delaware corporation (“Tenant”). RECITALS A.WHEREAS, Landlord and Tenant entered into that certain Lease dated as of Au |
|
| February 9, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 2) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Generation Bio Co. (Name of Subject Company) Generation Bio Co. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 37148K 209 (CUSIP Numbe |
|
| February 9, 2026 |
SECOND AMENDED AND RESTATED BYLAWS GENERATION BIO CO. (A DELAWARE CORPORATION) Exhibit 3.2 SECOND AMENDED AND RESTATED BYLAWS OF GENERATION BIO CO. (A DELAWARE CORPORATION) ARTICLE I Offices Section 1.Registered Office. The registered office of the corporation in the State of Delaware shall be Corporation Trust Center, 1209 Orange Street in the City of Wilmington, County of New Castle 19801, or in such other location as the Board of Directors may from time to time determine |
|
| February 9, 2026 |
As filed with the Securities and Exchange Commission on February 9, 2026 As filed with the Securities and Exchange Commission on February 9, 2026 Registration No. |
|
| February 9, 2026 |
As filed with the Securities and Exchange Commission on February 9, 2026 As filed with the Securities and Exchange Commission on February 9, 2026 Registration No. |
|
| February 9, 2026 |
As filed with the Securities and Exchange Commission on February 9, 2026 As filed with the Securities and Exchange Commission on February 9, 2026 Registration No. |
|
| January 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 1) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Generation Bio Co. (Name of Subject Company) Generation Bio Co. (Name of Persons Filing Statement) Common stock, par value $0.0001 per share (Title of Class of Securities) 37148K 209 (CUSIP Numbe |
|
| January 30, 2026 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 2) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 GENERATION BIO CO. (Name of Subject Company (Issuer)) XRA 7 CORP. (Name of Filing Persons (Co-Offeror)) XOMA ROYALTY CORPORATION (Name of Filing Persons (Co-Offeror)) Common Stock, Par Value |
|
| January 12, 2026 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Amendment No. 1) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 GENERATION BIO CO. (Name of Subject Company (Issuer)) XRA 7 CORP. (Name of Filing Persons (Co-Offeror)) XOMA ROYALTY CORPORATION (Name of Filing Persons (Co-Offeror)) Common Stock, Par Value |
|
| January 9, 2026 |
EX-99.(a)(1)(C) Exhibit (a)(1)(C) Offer to Purchase All Issued and Outstanding Shares of Common Stock of GENERATION BIO CO. A Delaware corporation at A Price per Share of $4.2913, Plus One Contingent Value Right (“CVR”) for Each Company Share, Which Represents the Right to Receive Potential Payments, in Cash, Contingent upon Receipt of Any CVR Proceeds, as Described in the CVR Agreement Pursuant t |
|
| January 9, 2026 |
MUTUAL NONDISCLOSURE AGREEMENT EX-99.(d)(2) Exhibit (d)(2) MUTUAL NONDISCLOSURE AGREEMENT This Nondisclosure Agreement (this “Agreement”) is made and entered into as of October 17, 2025 (the “Effective Date”), by and between Generation Bio Co., a Delaware corporation (the “Company”), and XOMA Royalty Corporation, a Nevada corporation (the “Recipient”). The Company and the Recipient are sometimes referred to herein individually |
|
| January 9, 2026 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Generation Bio Co. (Name of Subject Company) Generation Bio Co. (Name of Persons Filing Statement) Common stock, par value $0.0001 per share (Title of Class of Securities) 37148K 209 (CUSIP Numbe |
|
| January 9, 2026 |
EX-99.(a)(1)(A) Exhibit (a)(1)(A) Offer to Purchase All Issued and Outstanding Shares of Common Stock of GENERATION BIO CO. at A Price per Share of $4.2913, Plus One Contingent Value Right (“CVR”), Which Represents the Right to Receive Potential Payments, in Cash, Contingent upon Receipt of Any CVR Proceeds, as Described in the CVR Agreement by XRA 7 CORP. and XOMA ROYALTY CORPORATION THE OFFER AN |
|
| January 9, 2026 |
SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 GENERATION BIO CO. (Name of Subject Company (Issuer)) XRA 7 CORP. (Name of Filing Persons (Co-Offeror)) XOMA ROYALTY CORPORATION (Name of Filing Persons (Co-Offeror)) Common Stock, Par Value $0.0001 Per Share (T |
|
| January 9, 2026 |
Table 1: Transaction Valuation Calculation of Filing Fee Tables Table 1: Transaction Valuation Transaction Valuation Fee Rate Amount of Filing Fee Fees to be Paid 1 $ 36,392,847. |
|
| January 9, 2026 |
EX-99.(a)(1)(D) Exhibit (a)(1)(D) Offer to Purchase All Issued and Outstanding Shares of Common Stock of GENERATION BIO CO. At A Price per Share of $4.2913, Plus One Contingent Value Right (“CVR”) for Each Company Share, Which Represents the Right to Receive Potential Payments, in Cash, Contingent upon Receipt of Any CVR Proceeds, as Described in the CVR Agreement Pursuant to the Offer to Purchase |
|
| January 9, 2026 |
EX-99.(a)(1)(B) Exhibit (a)(1)(B) Letter of Transmittal To Tender Company Shares of Common Stock of GENERATION BIO CO. a Delaware corporation at A Price per Share of $4.2913, Plus One Contingent Value Right (“CVR”) for Each Company Share, Which Represents the Right to Receive Potential Payments, in Cash, Contingent upon Receipt of Any CVR Proceeds, as Described in the Offer to Purchase and the CVR |
|
| December 16, 2025 |
EX-99.1 Exhibit 99.1 XOMA Royalty Enters into Agreement to Acquire Generation Bio - Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio’s collaboration with Moderna - - Generation Bio’s cell-targeted lipid nanoparticles (ctLNP) delivery platform for small interfering RNA (siRNA) and other nucleic acid therapies to be included in XOMA Royalty’s portf |
|
| December 16, 2025 |
SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 GENERATION BIO CO. (Name of Subject Company (Issuer)) XOMA ROYALTY CORPORATION (Name of Filing Persons (Offeror 1)) XRA 7 CORP. (Name of Filing Persons (Offeror 2)) Common Stock, Par Value $0.0001 |
|
| December 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2025 Generation Bio Co. (Exact name of registrant as specified in its charter) Delaware 001-39319 81-4301284 (State or other jurisdiction of incorporation) (Commission Fi |
|
| December 15, 2025 |
Exhibit 99.1 XOMA Royalty Enters into Agreement to Acquire Generation Bio - Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio’s collaboration with Moderna - - Generation Bio’s cell-targeted lipid nanoparticles (ctLNP) delivery platform for small interfering RNA (siRNA) and other nucleic acid therapies to be included in XOMA Royalty’s portfolio - E |
|
| December 15, 2025 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER DATED AS OF DECEMBER 15, 2025 AMONG XOMA ROYALTY CORPORATION XRA 7 CORP. AND GENERATION BIO CO. TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 3 SECTION 1.01 Definitions 3 SECTION 1.02 Interpretation and Rules of Construction 16 ARTICLE II THE OFFER 17 SECTION 2.01 The Offer 17 SECTION 2.02 Company Actions 21 ARTICLE III THE MERGER 22 SECTION 3.01 The Merger |
|
| December 15, 2025 |
Exhibit 2.2 TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of December 15, 2025, is made by and among XOMA Royalty Corporation, a Nevada corporation (“Parent”), XRA 7 Corp., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and the undersigned holder (“Stockholder”) of shares of common stock, par value $0.0001 per share (the |
|
| December 15, 2025 |
FORM OF CONTINGENT VALUE RIGHTS AGREEMENT Exhibit 2.3 FORM OF CONTINGENT VALUE RIGHTS AGREEMENT This CONTINGENT VALUE RIGHTS AGREEMENT, dated as of (this “Agreement”), is entered into by and among XOMA Royalty Corporation, a Nevada corporation (“Parent”), XRA 7 Corp., a Delaware corporation and a wholly owned Subsidiary of Parent (“Merger Sub” and together with Parent, the “Buyer Entities”) and Broadridge Corporate Issuer Solutions, LLC, |
|
| December 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Generation Bio Co. (Name of Subject Company) Generation Bio Co. (Name of Persons Filing Statement) Common Stock, par value $0.0001 per share (Title of Class of Securities) 37148K 209 (CUSIP Number of Class of Secu |
|
| November 5, 2025 |
Cambridge, MA 02142 generationbio.com ` Exhibit 10.6 October 22, 2025 Geoff McDonough Re:Separation Agreement Dear Geoff: This letter confirms the terms of your separation from employment at Generation Bio Co. (the “Company”). Your employment with the Company terminates on October 31, 2025 (the “Extended Separation Date”). Please read this letter agreement (the “Agreement”), which includes a gener |
|
| November 5, 2025 |
Exhibit 10.9 By Electronic Mail October 22, 2025 Yalonda Howze Dear Yalonda: We would like to express our appreciation and commendation for all the passion and commitment you have been exhibiting in your existing role. In recognition of your contribution and leadership, it is my pleasure to inform you that, effective November 1, 2025, you will be promoted to Interim CEO & President. In connection |
|
| November 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3931 |
|
| November 5, 2025 |
Cambridge, MA 02142 generationbio.com Exhibit 10.10 October 22, 2025 Yalonda Howze Re:Separation Agreement Dear Yalonda: This letter confirms the terms of your separation from employment at Generation Bio Co. (the “Company”). If you timely sign and return this letter agreement, your employment with the Company terminates on March 31, 2026 (the “Extended Separation Date”). Please read this letter a |
|
| November 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 5, 2025 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| November 5, 2025 |
Exhibit 10.7 CONSULTING AGREEMENT This Consulting Agreement (the “Consulting Agreement”) made this November 1, 2025 (the “Effective Date”), is entered into by Generation Bio Co. (the “Company”) having a principal place of business at 301 Binney Street, Cambridge, Massachusetts 02142, and Geoff McDonough (the “Consultant”) having a residence at ***. WHEREAS, the Consultant served as the Company’s C |
|
| November 5, 2025 |
Exhibit 10.3 Cambridge, MA 02142 generationbio.com August 12, 2025 Kevin Conway Re:Separation Agreement Dear Kevin: This letter confirms the terms of your separation from employment at Generation Bio Co. (the “Company”). Your employment with the Company terminates on March 31, 2026 (the “Extended Separation Date”). Please read this letter agreement (the “Agreement”), which includes a general relea |
|
| November 5, 2025 |
Generation Bio Announces Third Quarter 2025 Financial Results Exhibit 99.1 Generation Bio Announces Third Quarter 2025 Financial Results CAMBRIDGE, MASS., November 5, 2025 - Generation Bio Co. (Nasdaq: GBIO), a biotechnology company, today reported third quarter financial results. Third Quarter 2025 Financial Results ● Cash Position: Cash, cash equivalents, and marketable securities were $89.6 million as of September 30, 2025, compared to $185.2 million as o |
|
| November 5, 2025 |
Exhibit 10.5 CONSULTING AGREEMENT This Consulting Agreement (the “Consulting Agreement”) made this November 1, 2025 (the “Effective Date”), is entered into by Generation Bio Co. (the “Company”) having a principal place of business at 301 Binney Street, Cambridge, Massachusetts 02142, and Phillip Samayoa (the “Consultant”) having a residence at ***. WHEREAS, the Consultant served as the Company’s C |
|
| November 5, 2025 |
Exhibit 10.8 Cambridge, MA 02142 generationbio.com August 26, 2025 Yalonda Howze Dear Yalonda, In recognition of our appreciation of your contributions to Generation Bio Co. (the “Company”) and to reward your continuing commitment, the Company is hereby offering you eligibility for a retention bonus equal to 100% of your base salary for each month of employment following August 15, 2025 until Marc |
|
| November 5, 2025 |
Exhibit 10.1 Cambridge, MA 02142 generationbio.com August 12, 2025 Antoinette Paone Re:Separation Agreement Dear Antoinette: This letter confirms the terms of your separation from employment at Generation Bio Co. (the “Company”). Your employment with the Company terminates on October 31, 2025 (the “Extended Separation Date”). Please read this letter agreement (the “Agreement”), which includes a ge |
|
| November 5, 2025 |
Exhibit 10.4 CONSULTING AGREEMENT This Consulting Agreement (the “Consulting Agreement”) made this November 1, 2025 (the “Effective Date”), is entered into by Generation Bio Co. (the “Company”) having a principal place of business at 301 Binney Street, Cambridge, Massachusetts 02142, and Antoinette Paone (the “Consultant”) having a residence at ***. WHEREAS, the Consultant served as the Company’s |
|
| November 5, 2025 |
Exhibit 10.2 Cambridge, MA 02142 August 12, 2025 generationbio.com Phillip Samayoa Re:Separation Agreement Dear Phillip: This letter confirms the terms of your separation from employment at Generation Bio Co. (the “Company”). Your employment with the Company terminates on October 31, 2025 (the “Extended Separation Date”). Please read this letter agreement (the “Agreement”), which includes a genera |
|
| October 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 21, 2025 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| October 22, 2025 |
Exhibit 99.1 Generation Bio Announces CEO Transition -Geoff McDonough, MD to step down as CEO & President and become Chair of the Company’s Board of Directors -Current Chief Legal Officer Yalonda Howze, JD named Interim CEO & President CAMBRIDGE, MASS., October 22, 2025 - Generation Bio Co. (Nasdaq: GBIO), a biotechnology company working to change what’s possible for people living with T cell-driv |
|
| August 12, 2025 |
2025 Inducement Stock Incentive Plan Exhibit 10.1 2025 INDUCEMENT STOCK INCENTIVE PLAN OF GENERATION BIO CO. 1. Purpose The purpose of this 2025 Inducement Stock Incentive Plan (the “Plan”) of Generation Bio Co., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to |
|
| August 12, 2025 |
Exhibit 99.1 CONFIDENTIAL Generation Bio Announces New Data for Its Novel ctLNP Delivery System and Early T Cell Programs and Reports Second Quarter 2025 Financial Results ● New data confirm highly selective profile of cell-targeted lipid nanoparticle (ctLNP) and first-ever siRNA delivery to T cells in non-human primates ● Lead siRNA candidates show potent knockdown of LAT1 and VAV1, targets poten |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39319 GEN |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 12, 2025 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 12, 2025 |
Form of Nonstatutory Stock Option Agreement under 2025 Inducement Stock Incentive Plan Exhibit 10.2 Generation Bio Co. NONSTATUTORY STOCK OPTION AGREEMENT Granted under 2025 Inducement Stock Incentive Plan Generation Bio Co. (the “Company”) hereby grants the following stock option to the recipient named below pursuant to its 2025 Inducement Stock Incentive Plan (as amended through the date hereof, the “Plan”). The terms and conditions attached hereto are also a part hereof and are i |
|
| July 18, 2025 |
Certificate of Amendment of Amended and Restated Certificate of Incorporation of Generation Bio Co. Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GENERATION BIO CO. Generation Bio Co., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is Generation Bio Co. The date of filing of the Corporation’s original Certificate of I |
|
| July 18, 2025 |
Generation Bio Announces 1-for-10 Reverse Stock Split Exhibit 99.1 Generation Bio Announces 1-for-10 Reverse Stock Split CAMBRIDGE, Mass. – July 18, 2025 – Generation Bio Co. (Nasdaq: GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, today announced that it will implement a 1-for-10 reverse stock split of the issued shares of the Company’s common stock (“Reverse Stock Split”), e |
|
| July 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 18, 2025 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 5, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 4, 2025 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 7, 2025 |
2025 Inducement Stock Incentive Plan of Registrant. Exhibit 99.1 2025 INDUCEMENT STOCK INCENTIVE PLAN OF GENERATION BIO CO. 1. Purpose The purpose of this 2025 Inducement Stock Incentive Plan (the “Plan”) of Generation Bio Co., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to |
|
| May 7, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 7, 2025 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 7, 2025 |
Form of Nonstatutory Stock Option Agreement Granted under 2025 Inducement Stock Incentive Plan. Exhibit 99.2 Generation Bio Co. NONSTATUTORY STOCK OPTION AGREEMENT Granted under 2025 Inducement Stock Incentive Plan Generation Bio Co. (the “Company”) hereby grants the following stock option to the recipient named below pursuant to its 2025 Inducement Stock Incentive Plan (as amended through the date hereof, the “Plan”). The terms and conditions attached hereto are also a part hereof and are i |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39319 GE |
|
| May 7, 2025 |
Exhibit 99.1 Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial Results - Company continues to advance its strategy to develop first-in-class treatments for T cell-driven autoimmune diseases using its cell-targeted lipid nanoparticle (ctLNP) technology to deliver siRNA - Lead target and portfolio strategy to be announced MY 2025 - Cash balance of $157.6 million exp |
|
| May 7, 2025 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Generation Bio Co. |
|
| May 7, 2025 |
As filed with the Securities and Exchange Commission on May 7, 2025 As filed with the Securities and Exchange Commission on May 7, 2025 Registration No. |
|
| April 23, 2025 |
Table of Contents will UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 23, 2025 |
Annual Report 2024 CHANGING WHAT’S POSSIBLE FOR PEOPLE LIVING WITH T CELL-DRIVEN AUTOIMMUNE DISEASETo our shareholders, I am pleased to share with you the significant progress Generation Bio has made over the past year and our strategic vision for the future. |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Filed by a Party other than the Registrant ☒ Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 11, 2025 |
Table of Contents will UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 13, 2025 |
Non-Employee Director Compensation Program. Exhibit 10.18 GENERATION BIO CO. Non-Employee Director Compensation Program Under Generation Bio Co.’s (the “Company”) non-employee director compensation program, the Company pays its non-employee directors an annual fee. Each non-employee director receives an annual fee for service on the Company’s board of directors (the “Board”) and for service on each committee on which the director is a membe |
|
| March 13, 2025 |
Exhibit 99.1 Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics for T cell-driven autoimmune diseases - Lead target and indication to be announced MY 2025 - Cash balance of $185.2 million expected to fund operations into 2H 2027 CAMBRIDGE, MASS., Mar. 13, 202 |
|
| March 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 13, 2025 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 13, 2025 |
Subsidiaries of the registrant. Exhibit 21.1 Subsidiaries of the Registrant Entity Jurisdiction of Incorporation Generation Bio Securities Corporation Massachusetts |
|
| March 13, 2025 |
Offer letter, dated December 8, 2017, by and between the registrant and Phillip Samayoa, as amended. Exhibit 10.20 Generation Bio Co. December 8, 2017 Phillip Samayoa Dear Phillip: On behalf of Generation Bio. Co. (the "Company"), I am pleased to offer you employment with the Company on the following terms and conditions. 1. Position. You will be employed by the Company as a Senior Director of Corporate Development and Portfolio Strategy. It is contemplated that you will commence employment on a |
|
| March 13, 2025 |
Cambridge, MA 02142 generationbio.com Exhibit 10.30 January 3, 2025 BY E-MAIL Matthew Stanton *** *** Dear Matt: This letter agreement (the “Agreement”) confirms the terms of your separation from employment at Generation Bio Co. (the “Company”)1 and the Company’s interest in securing your agreement to provide transition services on an as-needed basis and sets forth the terms and conditions to whic |
|
| March 13, 2025 |
Separation Agreement, by and between the registrant and Matt Norkunas, dated January 13, 2025. Cambridge, MA 02142 generationbio.com Exhibit 10.29 January 4, 2025 BY E-MAIL *** Dear Matt: This letter agreement (the “Agreement”) confirms the terms of your separation from employment at Generation Bio Co. (the “Company”)1. This Agreement will become effective and enforceable on the eighth day after you sign it without revocation (the “Effective Date”), provided you sign and return the Agreemen |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39 |
|
| March 13, 2025 |
Offer letter, dated December 8, 2017, by and between the registrant and Kevin Conway, as amended. Exhibit 10.28 By Electronic Mail June 25th, 2019 Kevin Conway RE: Offer of Employment Dear Kevin: We are very excited to offer you the position of Assistant Corporate Controller where you will play an essential role in building Generation Bio's foundation and long -term business and scientific success. Below are the terms of employment for your review and execution. If these terms are acceptable, |
|
| February 28, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 24, 2025 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| February 12, 2025 |
Exhibit 99 Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. |
|
| January 6, 2025 |
Exhibit 99.1 Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases - Novel programs will combine validated cell-targeted LNP (ctLNP) delivery with siRNA to selectively modulate T cells in vivo - Programs to focus on silencing hard-to-drug targets of high therapeutic value in T cell-driven autoimmune diseases - Company reorganization |
|
| January 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 6, 2025 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| January 3, 2025 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Generation Bio Co. |
|
| January 3, 2025 |
As filed with the Securities and Exchange Commission on January 3, 2025 As filed with the Securities and Exchange Commission on January 3, 2025 Registration No. |
|
| December 9, 2024 |
GBIO / Generation Bio Co. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d891686dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Generation Bio Co. (Name of Issuer) Common Stock (Title of Class of Securities) 37148K100 (CUSIP Number) December 5, 2024 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate t |
|
| November 14, 2024 |
GBIO / Generation Bio Co. / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment SC 13G/A 1 gbio13gasep24.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5) GENERATION BIO CO (Name of Issuer) COMMON STOCK (Title of Class of Securities) 37148K100 (CUSIP NUMBER) September 30, 2024 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule purs |
|
| November 8, 2024 |
GBIO / Generation Bio Co. / BlackRock, Inc. Passive Investment SC 13G 1 us37148k1007110824.txt us37148k1007110824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) Generation Bio Co. - (Name of Issuer) Common Stock - (Title of Class of Securities) 37148K100 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| November 6, 2024 |
Generation Bio Reports Recent Business Highlights and Third Quarter 2024 Financial Results ● Non-human primate data presented at ESGCT demonstrated selective in vivo delivery of mRNA with T cell-targeted lipid nanoparticle (ctLNP) ● Cash balance of $199. |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3931 |
|
| November 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 6, 2024 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| October 23, 2024 |
GBIO / Generation Bio Co. / BlackRock, Inc. Passive Investment SC 13G 1 us37148k1007102324.txt us37148k1007102324.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) Generation Bio Co. - (Name of Issuer) Common Stock - (Title of Class of Securities) 37148K100 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| August 13, 2024 |
August 13, 2024 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: Generation Bio Co. |
|
| August 12, 2024 |
August 12, 2024 Geoff McDonough, M.D. Chief Executive Officer Generation Bio Co. 301 Binney Street Cambridge, MA 02142 Re: Generation Bio Co. Registration Statement on Form S-3 Filed August 7, 2024 File No. 333-281335 Dear Geoff McDonough M.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for a |
|
| August 7, 2024 |
Exhibit 4.6 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE |
|
| August 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2024 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| August 7, 2024 |
Form of Subordinated Indenture Exhibit 4.4 GENERATION BIO CO. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE 1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) Ina |
|
| August 7, 2024 |
As filed with the Securities and Exchange Commission on August 7, 2024 Table of Contents As filed with the Securities and Exchange Commission on August 7, 2024 Registration No. |
|
| August 7, 2024 |
Exhibit 1.2 GENERATION BIO CO. $237,000,000 SALES AGREEMENT August 7, 2024 TD Securities (USA) LLC 1 Vanderbilt Avenue, 11th Floor New York, New York 10017 Ladies and Gentlemen: Generation Bio Co., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from tim |
|
| August 7, 2024 |
Exhibit 4.3 GENERATION BIO CO. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) Inapplicab |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39319 GEN |
|
| August 7, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Generation Bio Co. |
|
| August 7, 2024 |
Exhibit 99.1 Generation Bio Reports Second Quarter 2024 Financial Results ● Cash balance of $217 million still expected to fund operations into 2H 2027 CAMBRIDGE, MASS., Aug. 7, 2024 - Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and second quarter 2024 financial results. “We |
|
| August 7, 2024 |
Exhibit 4.5 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE |
|
| June 7, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 6, 2024 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39319 GE |
|
| May 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2024 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 13, 2024 |
Generation Bio Announces Recent Business Highlights and First Quarter 2024 Financial Results - Oral presentation at ASGCT described selective, high levels of therapeutic transgene delivery to T cells in vivo by cell-targeted lipid nanoparticle (ctLNP) - ASGCT poster presentations described immune-quiet DNA (iqDNA) as partially single-stranded, produced by flexible, scalable, proprietary rapid enzymatic synthesis - Cash balance of $233. |
|
| May 13, 2024 |
Separation Agreement, by and between the registrant and Tracy Zimmermann, dated January 28, 2024. Exhibit 10.2 Cambridge, MA 02142 generationbio.com November 29, 2023 Tracy Zimmermann *** *** Re:Separation Agreement Dear Tracy: This letter confirms the terms of your transition and separation from employment at Generation Bio Co. (the “Company”).1 As we discussed, the Company is reorganizing and, as a result, your position is being eliminated. You will continue to work and effect a transition o |
|
| May 13, 2024 |
Consulting Agreement, by and between the registrant and Doug Kerr, dated February 1, 2024. Exhibit 10.3 CONSULTING AGREEMENT GENERATION BIO CONTRACT NO. 21520 This Consulting Agreement (the “Agreement”) dated February 1, 2024 (the “Effective Date”), is made by and between Generation Bio Co., a Delaware corporation having a place of business at 301 Binney St., Suite 401, Cambridge, MA 02421 (the “Company”), and Douglas Kerr, an individual with an address at *** (the “Consultant”). WHEREA |
|
| May 13, 2024 |
Separation Agreement, by and between the registrant and Doug Kerr, dated January 28, 2024. Exhibit 10.1 Cambridge, MA 02142 generationbio.com November 29, 2023 Doug Kerr *** *** Re:Separation Agreement Dear Doug: This letter confirms the terms of your transition and separation from employment at Generation Bio Co. (the “Company”).1 As we discussed, the Company is reorganizing and, as a result, your position is being eliminated. You will continue to work and effect a transition of your d |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Filed by a Party other than the Registrant ☒ Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 24, 2024 |
Annual Report 2023To our shareholders, Last year was transformational for Generation Bio. |
|
| April 24, 2024 |
Table of Contents will UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39 |
|
| March 6, 2024 |
Subsidiaries of the registrant. Exhibit 21.1 Subsidiaries of the Registrant Entity Jurisdiction of Incorporation Generation Bio Securities Corporation Massachusetts |
|
| March 6, 2024 |
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results - Company is leveraging proprietary cell-targeted lipid nanoparticle delivery to develop wholly-owned in vivo program for sickle cell disease and beta-thalassemia - Development of breakthrough immune-quiet DNA for hemophilia A program continues - Cash balance of $264. |
|
| March 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 6, 2024 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| March 6, 2024 |
As filed with the Securities and Exchange Commission on March 6, 2024 As filed with the Securities and Exchange Commission on March 6, 2024 Registration No. |
|
| March 6, 2024 |
Insider Trading Policy of the registrant. Exhibit 19.1 GENERATION BIO CO. Insider Trading Policy 1. BACKGROUND AND PURPOSE The federal securities laws prohibit any member of the Board of Directors (a “Director”), officer (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934 (the “Exchange Act”), an “executive officer”) or employee of Generation Bio Co. (together with its subsidiaries, the “Company”) from purchasing or sel |
|
| March 6, 2024 |
Compensation Recovery Policy of the registrant. Exhibit 97.1 Generation Bio Co. Compensation Recovery Policy This Compensation Recovery Policy (this “Policy”) is adopted by Generation Bio Co. (the “Company”) in accordance with Nasdaq Listing Rule 5608 (“Rule 5608”), which implements Rule 10D-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (as promulgated pursuant to Section 954 of the Dodd-Frank Wall Street Reform a |
|
| March 6, 2024 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Generation Bio Co. |
|
| February 14, 2024 |
GBIO / Generation Bio Co. / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment SC 13G/A 1 gbio13gadec23.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) GENERATION BIO CO (Name of Issuer) COMMON STOCK (Title of Class of Securities) 37148K100 (CUSIP NUMBER) December 31, 2023 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursu |
|
| February 13, 2024 |
GBIO / Generation Bio Co. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Generation Bio Co. (Name of Issuer) Common Stock (Title of Class of Securities) 37148K100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| February 9, 2024 |
GBIO / Generation Bio Co. / FMR LLC Passive Investment SCHEDULE 13G Amendment No.5 GENERATION BIO COMMON STOCK Cusip #37148K100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #37148K100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 5,351,013 Item 6: 0 Item 7: 5,352,399 Item 8: 0 Item 9: 5,352,399 Item 11: 8.100% |
|
| February 9, 2024 |
GBIO / Generation Bio Co. / Atlas Venture Fund X, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm245794d2sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Generation Bio Co. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE (Title of Class of Securities) 37148K100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the app |
|
| February 2, 2024 |
Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 31, 2024 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 8, 2024 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| January 8, 2024 |
GBIO / Generation Bio Co. / BlackRock Inc. Passive Investment us37148k1007010824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) Generation Bio Co. - (Name of Issuer) Common Stock - (Title of Class of Securities) 37148K100 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| December 11, 2023 |
GBIO / Generation Bio Co / FMR LLC Passive Investment SCHEDULE 13G Amendment No.4 GENERATION BIO COMMON STOCK Cusip #37148K100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #37148K100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 6,561,973 Item 6: 0 Item 7: 6,563,359 Item 8: 0 Item 9: 6,563,359 Item 11: 9.932% |
|
| November 29, 2023 |
Generation Bio Announces Strategic Reorganization to Extend Cash Runway for Development of ctLNP and iqDNA Platforms - Company to invest in highly selective cell-targeted lipid nanoparticle (ctLNP) delivery platform to develop wholly-owned programs for extrahepatic cell types - Development of immune-quiet DNA (iqDNA) platform for lead hemophilia A program to continue - Strategic reorganization will result in a 40% reduction of workforce - Anticipated cost savings to extend cash runway into 2H 2027 CAMBRIDGE, MASS. |
|
| November 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 27, 2023 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3931 |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 9, 2023 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| November 9, 2023 |
Generation Bio Reports Business Highlights and Third Quarter 2023 Financial Results - Immune-quiet DNA evades innate immune sensors in both mice and non-human primates addressing a central challenge for non-viral DNA therapeutics - Proprietary cell-targeted LNP delivery system showed highly selective T cell transduction in humanized mouse model, demonstrating in vivo targeting for T cells and potentially for other extrahepatic tissues and cell types - Third quarter 2023 cash balance of $291. |
|
| October 26, 2023 |
Generation Bio Announces Demonstration of Highly Selective T Cell Transduction In Vivo with Cell-Targeted LNP Platform - 70% of circulating and splenic T cells positive for mRNA expression in humanized mice with less than 8% delivery to off-target immune cells - Stealth properties of cell-targeted lipid nanoparticle (ctLNP) platform confirmed in non-human primates, demonstrating prolonged circulation and less than 0. |
|
| October 26, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 26, 2023 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| October 18, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 18, 2023 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| October 18, 2023 |
Medicine Platform with Novel “Immune-Quiet” DNA Generation Bio Announces Breakthrough in its Non-Viral Genetic Medicine Platform with Novel “Immune-Quiet” DNA -Immune-quiet DNA (iqDNA) is a novel variant of closed-ended DNA (ceDNA) that evades host innate immune detection in both mice and non-human primates (NHPs) with a systemic cytokine profile and tolerability comparable to mRNA -Company is advancing iqDNA in lieu of prior ceDNA constructs a |
|
| August 2, 2023 |
Generation Bio Reports Second Quarter 2023 Financial Results Second quarter 2023 cash balance of $314. |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 2, 2023 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| August 2, 2023 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GENERATION BIO CO. Generation Bio Co., a corporation organized and existing under the General Corporation Law of the State of Delaware, does hereby certify that the name of the corporation is Generation Bio Co. and the original certificate of incorporation of the corporation was filed with the Secretary of State of the State of Delaw |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39319 GEN |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 8, 2023 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 10, 2023 |
Generation Bio Reports Business Highlights and First Quarter 2023 Financial Results Company entered into strategic collaboration with Moderna to use Generation Bio’s proprietary non-viral genetic medicine delivery system for two liver disease programs and to co-develop novel targeting for immune cells Factor VIII expression data in non-human primates for wholly-owned hemophilia A program expected in 2023 First quarter 2023 cash balance of $288. |
|
| May 10, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 10, 2023 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39319 GE |
|
| May 10, 2023 |
Exhibit 10.1 By Electronic Mail March 17, 2023 Yalonda Howze *** *** RE: Offer of Employment Dear Yalonda: We are very excited to offer you the position of Chief Legal Officer where you will play an essential role in building Generation Bio’s foundation and long-term business and scientific success. Below are the terms of employment for your review and execution. If these terms are acceptable, ple |
|
| May 10, 2023 |
Exhibit 10.2 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. COLLABORATION AND LICENSE AGREEMENT between GENERATION BIO CO. and MODERNATX, INC. dated March 23, 2023 TABLE OF CONTENTS Page ARTICLE 1 - DEFINITIONS AND INTE |
|
| May 10, 2023 |
Exhibit 10.3 Execution Version Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. SHARE PURCHASE AGREEMENT By and Between MODERNATX, INC. AND GENERATION BIO CO. Dated as of March 23, 2023 TABLE OF CONTENTS Page 1. Definitio |
|
| April 26, 2023 |
Annual Report 2022To our shareholders, Five years ago, we set out with the ambitious goal to deliver on the full promise of non-viral genetic medicine. |
|
| April 26, 2023 |
Table of Contents will UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Filed by a Party other than the Registrant ☒ Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 10, 2023 |
Table of Contents will UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 31, 2023 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| April 4, 2023 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF GENERATION BIO CO. TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Record Date for Stockholder Meetings 1 1.5 Notice of Meetings 1 1.6 Voting List 1 1.7 Quorum 2 1.8 Adjournments 2 1.9 Voting and Proxies 2 1.10 Action at Meeting 2 1.11 Nomination of Directors 3 1.12 Notice of Business |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 31, 2023 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 24, 2023 |
GBIO / Generation Bio Co / ModernaTX, Inc. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) * Generation Bio Co. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 37148K100 (CUSIP Number) March 24, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 23, 2023 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 10, 2023 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| February 23, 2023 |
Generation Bio Outlines 2023 Strategic Priorities and Reports Fourth Quarter and Full Year 2022 Financial Results - Company expects to announce data for Factor VIII expression in non-human primates in 2023 - Strong cash balance of $279. |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 23, 2023 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| February 23, 2023 |
Subsidiaries of the registrant. Exhibit 21.1 Subsidiaries of the Registrant Entity Jurisdiction of Incorporation Generation Bio Securities Corporation Massachusetts |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39 |
|
| February 14, 2023 |
GBIO / Generation Bio Co / PFM Health Sciences, LP - SC 13G/A Passive Investment SC 13G/A 1 tm235475d6sc13g.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1)* Generation Bio Co. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 37148K100 (CUSIP Number) December |
|
| February 14, 2023 |
GBIO / Generation Bio Co / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) GENERATION BIO CO (Name of Issuer) COMMON STOCK (Title of Class of Securities) 37148K100 (CUSIP NUMBER) December 31, 2022 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is |
|
| February 14, 2023 |
EX-99.B 2 d405438dex99b.htm EX-99.B Exhibit B POWER OF ATTORNEY The Undersigned, Hugo van Neutegem herewith gives Power of Attorney to Mrs. Nathalie M.A. Isidora-Kwidama, born in Curacao on, holder of a passport issued by the Kingdom of the Netherlands, with number, to represent the Company in the broadest sense of the word and in the best interest of the Company and further to do if were the Unde |
|
| February 14, 2023 |
GBIO / Generation Bio Co / T. Rowe Price Investment Management, Inc. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) GENERATION BIO CO (Name of Issuer) COMMON STOCK (Title of Class of Securities) 37148K100 (CUSIP NUMBER) December 31, 2022 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is |
|
| February 14, 2023 |
GBIO / Generation Bio Co / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Generation Bio Co. (Name of Issuer) Common Stock (Title of Class of Securities) 37148K100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| February 9, 2023 |
GBIO / Generation Bio Co / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0971-generationbioco.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Generation Bio Co. Title of Class of Securities: Common Stock CUSIP Number: 37148K100 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate |
|
| February 9, 2023 |
GBIO / Generation Bio Co / FMR LLC Passive Investment SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.3 GENERATION BIO COMMON STOCK Cusip #37148K100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #37148K100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 8,913,331 Item 6: 0 Item 7: 8,913,331 Item 8: 0 Item 9: 8,91 |
|
| February 1, 2023 |
GBIO / Generation Bio Co / BlackRock Inc. Passive Investment SC 13G/A 1 us37148k1007020123.txt us37148k1007020123.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) Generation Bio Co. - (Name of Issuer) Common Stock - (Title of Class of Securities) 37148K100 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 1, 2023 |
GBIO / Generation Bio Co / Farallon Capital Partners, L.P. - AMENDMENT #3 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 12, 2023 |
As filed with the Securities and Exchange Commission on January 12, 2023 As filed with the Securities and Exchange Commission on January 12, 2023 Registration No. |
|
| January 12, 2023 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Generation Bio Co. |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| November 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 3, 2022 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) ? Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) ? (Commission |
|
| November 3, 2022 |
Generation Bio Reports Business Highlights and Third Quarter 2022 Financial Results ? Cash balance of $301. |
|
| November 3, 2022 |
Exhibit 10.1 ? Generation Bio Co. ? ? ? ? December 8, 2017 ? Phillip Samayoa ? ? ? Dear Phillip: ? On behalf of Generation Bio. Co. (the "Company"), I am pleased to offer you employment with the Company on the following terms and conditions. ? 1. Position. You will be employed by the Company as a Senior Director of Corporate Development and Portfolio Strategy. It is contemplated that you will comm |
|
| September 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 15, 2022 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| September 6, 2022 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the common stock of Generation Bio Co., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the unders |
|
| September 6, 2022 |
GBIO / Generation Bio Co / PFM Health Sciences, LP - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* Generation Bio Co. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 37148K100 (CUSIP Number) August 25, 2022 (Date of Event Which Requires Fili |
|
| August 4, 2022 |
Generation Bio Reports Business Highlights and Second Quarter 2022 Financial Results ? Cash balance of $312. |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 4, 2022 |
Exhibit 10.1 ? GENERATION BIO CO. Non-Employee Director Compensation Program Under Generation Bio Co.?s (the ?Company?) non-employee director compensation program, the Company pays its non-employee directors an annual fee. Each non-employee director receives an annual fee for service on the Company?s board of directors (the ?Board?) and for service on each committee on which the director is a memb |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 4, 2022 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) ? Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) ? (Commission F |
|
| July 18, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 15, 2022 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) ? Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) ? (Commission Fi |
|
| June 21, 2022 |
? Generation Bio Announces Update to Its GMP Manufacturing Strategy ? Company projects smaller GMP manufacturing footprint, enabled by further process development of rapid enzymatic synthesis of ceDNA at scale ? Company will seek to sublease its planned GMP facility, and will adopt a more capital efficient, modular, and flexible manufacturing approach ? Capital reallocated from facility buildout expected to extend cash runway into 2025 ? Cambridge, Mass. |
|
| June 21, 2022 |
Financial Statements and Exhibits, Other Events ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 21, 2022 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) ? Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) ? (Commission Fi |
|
| June 10, 2022 |
Submission of Matters to a Vote of Security Holders ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 9, 2022 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) ? Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) ? (Commission Fil |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 5, 2022 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 5, 2022 |
Exhibit 10.2 THIRD AMENDMENT TO LEASE THIS THIRD AMENDMENT TO LEASE (this "Amendment") is entered into as of this 24th day of February, 2022 (the "Effective Date"), by and between BMR-ROGERS STREET LLC, a Delaware limited liability company ("Landlord"), and GENERATION BIO CO., a Delaware corporation ("Tenant"). RECITALS A.WHEREAS, Landlord and Tenant are parties to that certain Lease dated as of |
|
| May 5, 2022 |
Generation Bio Reports Business Highlights and First Quarter 2022 Financial Results Company continues to optimize cell-targeted lipid nanoparticle (ctLNP) delivery system for nonviral genetic medicine applications in liver, retina and vaccines Cash balance of $337. |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39319 GE |
|
| April 26, 2022 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 26, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? ? ? ? ? Filed by the Filed by a Party other than the Registrant ? ? Registrant ? ? ? Check the appropriate box: ? ? ? ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by |
|
| February 24, 2022 |
Exhibit 10.22 Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. ? AMENDMENT # 2 TO EXCLUSIVE LICENSE AGREEMENT Between Generation Bio and UMASS Chan Medical School ? This Amendment #2 (?Amendment 2?) expressly amends and relates to t |
|
| February 24, 2022 |
Subsidiaries of the registrant. Exhibit 21.1 ? Subsidiaries of the Registrant ? ? ? ? Entity Jurisdiction of Incorporation Generation Bio Securities Corporation ? Massachusetts ? |
|
| February 24, 2022 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 24, 2022 |
As filed with the Securities and Exchange Commission on February 24, 2022 As filed with the Securities and Exchange Commission on February 24, 2022 Registration No. |
|
| February 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 24, 2022 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) ? Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) ? (Commissio |
|
| February 24, 2022 |
Post-Effective Amendment No. 1 Table of Contents As filed with the Securities and Exchange Commission on February 24, 2022 Registration No. |
|
| February 24, 2022 |
Exhibit 10.20 Torus Therapeutics, Inc. ? ? ? ? September 5, 2017 ? Matthew Stanton ? Dear Matt: On behalf of Torus Therapeutics (the "Company"), I am pleased to offer you employment with the Company on the following terms and conditions. 1.Position. You will be employed by the Company as the Chief Technology Officer. It is contemplated that you will commence employment on a date to be mutually agr |
|
| February 24, 2022 |
As filed with the Securities and Exchange Commission on February 24, 2022 Table of Contents As filed with the Securities and Exchange Commission on February 24, 2022 Registration No. |
|
| February 24, 2022 |
Calculation of Filing Fee Table EX-FILING FEES 4 tmb-20220224xexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Generation Bio Co. (Exact Name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate |
|
| February 24, 2022 |
? ? Generation Bio Outlines 2022 Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results ? Well-capitalized with $375. |
|
| February 24, 2022 |
? ? ?Exhibit 10.21 ? By Electronic Moil ? October 11, 2018 ? Antoinette Drahus Paone ? RE: Offer of Employment ? Dear Antoinette: ? We are very excited to offer you the position of Vice President, Regulatory Affairs where you will play an essential role in building Generation Bio's foundation and long -term business and scientific success. Below are the terms of employment for your review and exec |
|
| February 24, 2022 |
Non-Employee Director Compensation Program. Exhibit 10.23 ? GENERATION BIO CO. Non-Employee Director Compensation Program Under Generation Bio Co.?s (the ?Company?) non-employee director compensation program, the Company pays its non-employee directors an annual fee. Each non-employee director receives an annual fee for service on the Company?s board of directors (the ?Board?) and for service on each committee on which the director is a mem |
|
| February 24, 2022 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Post-Effective Amendment No 1 to Form S-3 (Form Type) Generation Bio Co. |
|
| February 14, 2022 |
GBIO / Generation Bio Co / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Generation Bio Co. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 37148K100 (CUSIP NUMBER) December 31, 2021 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule i |
|
| February 11, 2022 |
GBIO / Generation Bio Co / Artal International S.C.A. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 2) Generation Bio Co. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 37148K100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| February 11, 2022 |
Atlas Venture Fund X, L.P. SC 13G/A Exhibit A JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Generation Bio Co. and further agree that this agreement be included as an ex |
|
| February 11, 2022 |
GBIO / Generation Bio Co / Atlas Venture Fund X, L.P. - AMENDMENT TO SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Generation Bio Co. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE (Title of Class of Securities) 37148K100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursua |
|
| February 11, 2022 |
GBIO / Generation Bio Co / BB BIOTECH AG - SC 13G/A Passive Investment United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Generation Bio Co. (Name of Issuer) Common Stock (Title of Class of Securities) 37148K100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| February 10, 2022 |
GBIO / Generation Bio Co / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Generation Bio Co. Title of Class of Securities: Common Stock CUSIP Number: 37148K100 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule 13d-1(b) ??Rule |
|
| February 10, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 4, 2022 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) ? Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) ? (Commission |
|
| February 9, 2022 |
GBIO / Generation Bio Co / FMR LLC Passive Investment SCHEDULE 13G Amendment No. 2 GENERATION BIO COMMON STOCK Cusip #37148K100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #37148K100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 2,603,752 Item 6: 0 Item 7: 8,536,462 Item 8: 0 Item 9: 8,536,462 Item 11: 14.999 |
|
| February 4, 2022 |
GBIO / Generation Bio Co / BlackRock Inc. Passive Investment us37148k1007020422.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) Generation Bio Co. - (Name of Issuer) Common Stock - (Title of Class of Securities) 37148K100 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 3, 2022 |
GBIO / Generation Bio Co / FARALLON CAPITAL MANAGEMENT LLC - AMENDMENT #2 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 10, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 10, 2022 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) ? Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) ? (Commission |
|
| December 14, 2021 |
EX-99.1 2 gbio-20211214xex99d1.htm EX-99.1 Generation Bio Provides Update on Preclinical Studies for Hemophilia A Program - Innovations in closed-ended DNA (ceDNA) and cell-targeted lipid nanoparticle (ctLNP) production processes generated peak mean of 205% normal human factor VIII expression in mice - Non-human primates (NHPs) demonstrated up to 2% normal human factor VIII expression, and higher- |
|
| December 14, 2021 |
Financial Statements and Exhibits, Other Events ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 14, 2021 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) ? Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) ? (Commissio |
|
| November 10, 2021 |
? ? ? ? ? 41 SEYON STREET WALTHAM, MASSACHUSETTS ? ? Lease to ? GENERATION BIO CO. |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| November 10, 2021 |
? ? Generation Bio Reports Business Highlights and Third Quarter 2021 Financial Results ? New preclinical retinal data illustrating potential for expansive therapeutic applications of ctLNP delivery presented at ESGCT 2021 Annual Virtual Congress ? CAMBRIDGE, MASS. |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 10, 2021 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) ? Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) ? (Commissio |
|
| August 11, 2021 |
Exhibit 4.4 GENERATION BIO CO. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE 1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) Ina |
|
| August 11, 2021 |
Exhibit 4.6 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE |
|
| August 11, 2021 |
Exhibit 4.5 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE |
|
| August 11, 2021 |
Generation Bio Reports Business Highlights and Second Quarter 2021 Financial Results Exhibit 99.1 ? ? ? Generation Bio Reports Business Highlights and Second Quarter 2021 Financial Results ? ? CAMBRIDGE, MASS., Aug. 11, 2021 - Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported recent business highlights and second quarter 2021 financial results. ? ?This quarter we announced our shift |
|
| August 11, 2021 |
Exhibit 1.2 GENERATION BIO CO. $250,000,000 SALES AGREEMENT August 11, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Generation Bio Co., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the |
|
| August 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 11, 2021 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) ? Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) ? (Commission |
|
| August 11, 2021 |
As filed with the Securities and Exchange Commission on August 11, 2021 Table of Contents As filed with the Securities and Exchange Commission on August 11, 2021 Registration No. |
|
| August 11, 2021 |
Exhibit 4.3 GENERATION BIO CO. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) Inapplicab |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| July 14, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 13, 2021 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) ? Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) ? (Commission Fi |
|
| July 14, 2021 |
? ? ? Generation Bio Announces Plan to Scale Next-Generation Rapid Enzymatic Manufacturing Process Across Portfolio and Provides Pipeline Update ? Company to transition all portfolio programs to rapid enzymatic synthesis (RES), enabling improved quality, scale and speed of closed-ended DNA manufacturing ? Lease agreement signed to build an in-house RES manufacturing facility providing cGMP capacity for and internal control over clinical and initial commercial supply ? IND submission for hemophilia A now planned for 2023; factor VIII expression data with RES material in non-human primates expected year-end 2021 ? Cambridge, Mass. |
|
| June 10, 2021 |
Submission of Matters to a Vote of Security Holders ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 9, 2021 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) ? Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) ? (Commission Fil |
|
| May 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 12, 2021 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) ? Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) ? (Commission Fil |
|
| May 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 12, 2021 |
? ? Generation Bio Presents Preclinical Data Demonstrating Broad Potential of Gene Therapy Platform at ASGCT and Reports First Quarter Financial Results ? Durable, therapeutically relevant levels of anti-SARS-CoV-2 spike antibodies produced from the liver in a mouse model ? Next-generation rapid enzymatic synthesis of closed-ended DNA further increases the efficiency and scale of the manufacturing platform ? Potent factor VIII construct optimized by taking advantage of the increased cargo capacity of closed-ended DNA ? CAMBRIDGE, MASS. |
|
| April 27, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 27, 2021 |
DEF 14A 1 tmb-20210609xdef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Filed by a Party other than the Registrant ☒ Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of th |
|
| March 18, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39 |
|
| March 18, 2021 |
As filed with the Securities and Exchange Commission on March 18, 2021 Registration No. |
|
| March 18, 2021 |
Exhibit 4.3 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED The following description of the capital stock and provisions of Generation Bio Co.?s (the ?Company,? ?we,? ?us? and/or ?our?) restated certificate of incorporation and amended and restated bylaws are summaries and are qualified by reference to our restated certif |
|
| March 18, 2021 |
Subsidiaries of the registrant. Exhibit 21.1 Subsidiaries of the Registrant Entity Jurisdiction of Incorporation Generation Bio Securities Corporation Massachusetts |
|
| March 18, 2021 |
EX-99.1 Exhibit 99.1 Generation Bio Reports Fourth Quarter and Full Year 2020 Financial Results $262.3 million cash balance at the end of 2020 bolstered by additional net proceeds of $211.3 million from follow-on offering, funding key milestones into 2024 Ron Cooper appointed to Board of Directors Company remains on track to begin IND-enabling studies for hemophilia A in 2021 CAMBRIDGE, MASS., Mar |
|
| March 18, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 18, 2021 Generation Bio Co. (Exact Name of Registrant as Specified in Charter) Delaware 001-39319 81-4301284 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
